Clinical Trial

PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma

Name: PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma — clinical trial record (NCT07641010)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

A prospective, multicenter, randomized controlled clinical study of camrelizumab in combination with ivarmacitinib as first-line treatment for pediatric classical Hodgkin lymphoma

Trial Details

NCT Number	NCT07641010
Lead Sponsor	Shanghai Jiao Tong University School of Medicine
Conditions	Hodgkin Lymphoma
Enrollment	112 participants
Start Date	2026-06-30
Primary Completion	2028-09-30 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-06-11